Home Cart Sign in  
Chemical Structure| 1370651-20-9 Chemical Structure| 1370651-20-9

Structure of Ensartinib
CAS No.: 1370651-20-9

Chemical Structure| 1370651-20-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ensartinib is a novel, potent anaplastic lymphoma kinase (ALK) small molecule tyrosine kinase inhibitor (TKI) with additional activity against MET, ABL, Axl, EPHA2, LTK, ROS1 and SLK. ALK autophosphorylation is significantly diminished by X-396, albeit at higher concentrations required to block autophosphorylation of the wild-type fusion.

Synonyms: X-396

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ensartinib

CAS No. :1370651-20-9
Formula : C26H27Cl2FN6O3
M.W : 561.44
SMILES Code : O=C(C1=NN=C(N)C(O[C@@H](C2=C(Cl)C=CC(F)=C2Cl)C)=C1)NC3=CC=C(C(N4C[C@@H](C)N[C@@H](C)C4)=O)C=C3
Synonyms :
X-396
MDL No. :MFCD31631377

Safety of Ensartinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Ensartinib

RTK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06762327 Solid Tumors PHASE2 NOT_YET_RECRUITING 2027-12-30 -
NCT05380024 Non Small Cell Lung Cancer PHASE2 UNKNOWN 2024-06-30 Beijing Cancer Hospital, Beiji... More >>ng, Beijing, 100142, China|NAN Wu, Beijing, Beijing, 100142, China Less <<
NCT06785584 ALK-positive Advanced NSCLC|AL... More >>K-positive Non-small Cell Lung Cancer (NSCLC)|MPR|Neoadjuvant Therapy Less << PHASE4 NOT_YET_RECRUITING 2025-12-01 Fujian Medical University Unio... More >>n Hospital, Fuzhou, Fujian, 350100, China Less <<
NCT06779539 Non-Small Cell Lung Cancer PHASE2 NOT_YET_RECRUITING 2030-12-12 -
NCT04146571 Non-Small Cell Lung Cancer|ALK... More >> Gene Rearrangement Positive Less << AVAILABLE - Stanford University, Stanford,... More >> California, 94305, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, 20889, United States|Vanderbilt University, Nashville, Tennessee, 37240, United States|University of Wisconsin Carbone Cancer Ctr, Madison, Wisconsin, 53792, United States Less <<
NCT05178511 The Diagnosis Was ALK Positive... More >> NSCLC|Second Generation ALK-TKI is Resistant|Efficacy of Ensatinib in This Subset of Patients Less << PHASE2 UNKNOWN 2024-12-31 Sun Yat-sen University, Guangz... More >>hou, Guangdong, 510060, China Less <<
NCT05498064 Carcinoma, Non-Small-Cell Lung... More >>|Anaplastic Lymphoma Kinase I1171N|Ensartinib Less << RECRUITING 2028-12-01 Department of Respiratory and ... More >>Critical Care Medicine, Peking Union Medical College Hospital, Beijing, Beijing, 100730, China Less <<
NCT05241028 Non-small Cell Lung Cancer PHASE2 RECRUITING 2029-02-01 Jun Feng Liu, Shijiazhuang, He... More >>bei, 050011, China Less <<
NCT02959619 Solid Tumor|Non-Small Cell Lun... More >>g Cancer Metastatic Less << PHASE1 COMPLETED 2020-04-23 Sun yat-sen Univerisity Cancer... More >> Center, Guanzhou, Guangdong, 510060, China Less <<
NCT06780839 NSCLC, Stage I, II, IIIA, IIIB PHASE2 NOT_YET_RECRUITING 2030-01-15 Beijing cancer hospital, Beiji... More >>ng, Beijing, 100000, China Less <<
NCT03804541 ALK-POSITIVE NSCLC PHASE1 UNKNOWN 2025-10-19 Jiangsu Province Hospital Affi... More >>liated to Nanjing Madical University of Medicine, Nanjing, Jiangsu Provence, 210005, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.78mL

0.36mL

0.18mL

8.91mL

1.78mL

0.89mL

17.81mL

3.56mL

1.78mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories